Hemp vs. heart meds: new study reveals CBD-Drug interaction risks
NCT ID NCT06692933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study looks at how two different doses of CBD (from hemp) change the amount of the blood thinner clopidogrel in the body. Researchers will enroll 24 healthy adults who have used cannabis before. The goal is to help doctors give better advice about using CBD safely with this common heart medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 21-64 years old and healthy; * Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer; * Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel; * Have taken hemp or cannabis (in any form) before and tolerated it well; * Willing to abstain from consuming dietary supplements/botanical products and citrus juices for the duration of the study; * Willing to abstain from cannabis/marijuana, hemp, THC- and/or CBD-containing products for several weeks; * Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day; * Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day; * Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study; * Have the ability to and are willing to comply with the requirements of the study; * Geographically located within a 40-mile radius of Spokane and have the time to participate and; * Can read and speak English Exclusion Criteria: * Under the age of 21 or over the age of 64; * Any major illness; * Pregnant or nursing; * History of allergy or intolerance to cannabis or clopidogrel; * Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel; * Never taken cannabis (in any form) before; * Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data; * Currently using or have recently used drugs or other illicit substances for recreational purposes; * Have used cannabis/marijuana, hemp, THC- and/or CBD-containing products within the last 4 weeks; * Have an out-of-range clinical laboratory value such that the study physician considers participation in the study a health risk, or; * Unable to read and speak English
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Interaction are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Washington State University College of Pharmacy and Pharmaceutical Sciences
RECRUITINGSpokane, Washington, 99202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.